162 related articles for article (PubMed ID: 17637545)
21. Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy.
Bouzani M; Karmiris T; Rontogianni D; Delimpassi S; Apostolidis J; Mpakiri M; Nikiforakis E
Oncologist; 2006 Sep; 11(8):923-8. PubMed ID: 16951396
[TBL] [Abstract][Full Text] [Related]
22. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
23. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
24. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.
DiJoseph JF; Dougher MM; Evans DY; Zhou BB; Damle NK
Cancer Chemother Pharmacol; 2011 Apr; 67(4):741-9. PubMed ID: 20521053
[TBL] [Abstract][Full Text] [Related]
25. Generalized B-cell non Hodgkin's lymphoma in association with leukocytoclastic vasculitis and disseminated intravascular coagulation.
Cardinali C; Santini S; di Leo A; Giannini A; Lo Scocco G
Dermatol Online J; 2006 Mar; 12(3):15. PubMed ID: 16638429
[TBL] [Abstract][Full Text] [Related]
26. [The standard treatments for patients with hematological malignancies in Japan].
Ishizawa K
Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
[TBL] [Abstract][Full Text] [Related]
27. Outcome of B-cell non-Hodgkin lymphoma protocol CCCG-B NHL97: a report from Chinese multi-center cooperative group.
Tang JY; Pan C; Chen J; Chen H; Wu Y; Xue H; Zhao H; Gu LJ; Fu RY; Wang YP
Med Pediatr Oncol; 2002 Sep; 39(3):212-4. PubMed ID: 12210455
[No Abstract] [Full Text] [Related]
28. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
29. [A case of primary malignant lymphoma of the bladder].
Nishida S; Kuroko K; Hoshino T; Iwamoto T; Shirai C
Hinyokika Kiyo; 1998 Aug; 44(8):599-601. PubMed ID: 9783199
[TBL] [Abstract][Full Text] [Related]
30. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract][Full Text] [Related]
31. Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.
Friedberg JW
Clin Cancer Res; 2004 Aug; 10(16):5297-8. PubMed ID: 15328164
[No Abstract] [Full Text] [Related]
32. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
33. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
34. Effect of combination chemotherapy with cefoperazone on non-Hodgkin's lymphoma.
Natazuka T; Matsui T; Ito M; Sugimoto T; Nakao Y; Fujita T
Leuk Res; 1992; 16(4):417-8. PubMed ID: 1373460
[No Abstract] [Full Text] [Related]
35. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
36. Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP.
Feldmann G; Nattermann J; Gerhardt T; Nähle CP; Spengler U; Woitas R
Int J Lab Hematol; 2007 Dec; 29(6):469-73. PubMed ID: 17988304
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis, care, and therapeutic possibilities in intravascular B-cell lymphoma--a case report].
Takács I; Tordai L; Eros N; Mórocz I; Bozsó F; Károlyi Z; Radványi G; Matolcsy A
Orv Hetil; 2005 May; 146(18):843-8. PubMed ID: 15926630
[TBL] [Abstract][Full Text] [Related]
38. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
Pro B; Leber B; Smith M; Fayad L; Romaguera J; Hagemeister F; Rodriguez A; McLaughlin P; Samaniego F; Zwiebel J; Lopez A; Kwak L; Younes A
Br J Haematol; 2008 Nov; 143(3):355-60. PubMed ID: 18764869
[TBL] [Abstract][Full Text] [Related]
39. A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy.
Kamata M; Sugaya M; Miyagaki T; Sonoda K; Ichimura Y; Mitsui H; Sato S; Kamikubo Y; Kurokawa M
Int J Dermatol; 2014 Jan; 53(1):e24-6. PubMed ID: 23452101
[No Abstract] [Full Text] [Related]
40. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
